Table 1.
Types of information extracted from each manuscript and stored as entries in the PTSDDB. For each data category, extensive information was curated and stored as separate entries in the PTSDDB. For example, the Data Category “Biomarker” includes information on Biomarker name, HUGO ID or another acronym, gene symbol/identifier, and biomarker application (e.g., biomarkers for disease risk, patient stratification, diagnostic marker, predictive markers of disease severity or treatment response, and safety/toxicity biomarkers).
| Model/data category | Fields |
|---|---|
| Publication | PubMed identifier, authors information (e.g. names, year of publication and geographical information) |
| Biomarker | Biomarker name, HUGO ID or other acronym, gene symbol, biomarker application. Protein, gene or miRNA biomarkers are coded using the HGNC nomenclature if possible. Small molecules nomenclatures are prioritized in the following order: ChEBI, PubChem and InChIKeys. |
| Time point | Study time point (e.g. 6 weeks post-trauma, 2 years post-trauma) |
| Approach panel details | Name, statistical method, cutoff used (e.g. P-value, False Discovery Rate, etc.), whether the biomarker was part of a panel, other analytes included, risk SNP, allele risk and additional notes on risk SNP |
| Numerical summary | Statistics (i.e. mean and standard deviation [SD]) about the biomarker measurements for primary indication, trauma-exposed controls, other central nervous system and healthy controls |
| Clinical instrument | Clinical instrument for primary indication, trauma in adult, childhood and lifetime (e.g. Clinician-Administered PTSD SCALE [CAPS], PTSD Checklist [PCL], Structured Clinical Interview for DSM-5 [SCID], etc.) |
| Clinical study | Type of study (e.g. cross-sectional, longitudinal), timeline, challenge type, treatment response study, number of subjects per indication (e.g. trauma-exposed PTSD, trauma-exposed controls, healthy controls, other indications) |
| Indication | Name and specifics of the condition (e.g. PTSD, childhood trauma, maternal PTSD) |
| Comorbidity | Name, comorbidity measurements (e.g. mean and SD) |
| Numerical readouts | Statistical details of each different group included in the study (e.g. mean, SD of the biomarker for primary indication or control) |
| Inclusion/exclusion criteria | The description of inclusion and exclusion criteria provided by each publication |
| Cohort name and demographic details | Details about the cohort (e.g. percent female plus the overall mean and SD in trauma-exposed PTSD vs trauma-exposed and healthy controls, mean age and SD age of subjects) |
| Ancestry | Ancestry details for Caucasian, African American and other ancestry of the cohort (e.g. percentage of each group included in the study) |
| Study findings | Direction of change of the biomarker in cases vs controls as specified by the study authors (e.g. increased, no change, decreased), specific circuit changes, notes and descriptions |
| Assay | Assay details: assay brand, probe, fluid, biological substrate, assay brand, assay limit detection and measurement units |
| Assay calculations | Mean and SD concentration (in primary indication, trauma-exposed controls, healthy controls and CNS controls), sigma combined and effect size |
| Statistical info | Mean, SD and variance, methylation change, t and P-value |